FSD Pharma Inc. (C:HUGE*CA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: First Canadian Place
100 King Street West, Suite 4000
TORONTO ON M5X 1A4
Tel: N/A
Website: https://www.fsdpharma.com
IR: See website
<
Key People
Anthony Durkacz
Co-Chairman of the Board, Executive Director
Zeeshan Saeed
Chief Executive Officer
Nathan Coyle
Chief Financial Officer
Donal Carroll
Chief Operating Officer
Kevin Cassidy
Vice President - Quality of Lucid
Andrzej Chruscinski
Vice President - Clinical and Scientific Affairs
Business Overview
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company's two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company's Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
Financial Overview
For the nine months ended 30 September 2023, FSD Pharma Inc revenues was not reported. Net loss before extraordinary items decreased 19% to $16.6M. Lower net loss reflects Gain on remeasurement of financial liabi increase from $120K to $4.9M (income), General and administrative decrease of 37% to $7.7M (expense), Depreciation and amortization decrease of 29% to $2.4M (expense).
Employees: 10 as of Dec 31, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $16.59M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$28.15M as of Sep 30, 2023
Net annual income (TTM): -$30.78M as of Sep 30, 2023
Free cash flow (TTM): -$22.07M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 40,090,921 as of Mar 11, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.